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ABSTRACT  
Background. Alport syndrome is a clinically and genetically heterogeneous nephropathy 
characterized by glomerular basement membrane lesions often associated with hearing loss and 
ocular anomalies. While the X-linked and the autosomal recessive forms are well known, the 
autosomal dominant form is not well acknowledged. 
 
Methods. We have clinically investigated 38 patients with a diagnosis of autosomal dominant 
Alport syndrome belonging to eight different families. The analysis of the COL4A4 gene was 
performed by denaturing high performance liquid chromatography and automated DNA 
sequencing. 
 
Results. In our cohort of patients, only 24.3% (9/37) reached end-stage renal disease, at the mean 
age of 51.2 years. Four patients had hearing loss (13.3%) and none ocular changes. Molecular 
analysis revealed eight novel private COL4A4 gene mutations: three frameshift, three missense and 
two splice-site mutations. 
 
Conclusions. These data indicate autosomal dominant Alport syndrome as a disease with a low risk 
of ocular and hearing anomalies but with a significant risk to develop renal failure although at an 
older age than the X-linked form. We were unable to demonstrate a genotype–phenotype 
correlation. Altogether, these data make difficult the differential diagnosis with the benign familial 
haematuria due to heterozygous mutations of COL4A4 and COL4A3, especially in young patients, 
and with the X-linked form of Alport syndrome in families where only females are affected. A 
correct diagnosis and prognosis is based on a comprehensive clinical investigation in as many 
family members as possible associated with a broadly formal genetic analysis of the pedigree.  
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INTRODUCTION 
Alport syndrome (ATS) is a progressive heterogeneous nephropathy characterized by the 
association of progressive haematuric nephritis with ultrastructural changes of the glomerular 
basement membrane (GBM), sensorineural deafness and variable ocular abnormalities [1–3]. ATS 
accounts for 1–2% of all patients who start renal replacement therapy in Europe, with an estimate 
frequency of about 1 in 5000 [4–6]. 
ATS is characterized by changes of type IV collagen α3, α4 and α5 network of the GBM, and three 
modes of inheritance are known. The X-linked inheritance, due to mutations in COL4A5 located in 
Xq22.3, is the most common mode of transmission (XLAS, OMIM 301050). In this form, 70% of 
affected males reach end-stage renal disease (ESRD) before 30 years (juvenile form), while only 
few cases (30%) progress towards ESRD after 30 years (rare adult form) [4,5,7]. Usually, females 
have only microhaematuria; however, a small percentage of females can develop renal failure. The 
autosomal recessive (ARAS, OMIM 203780) form of the disease is due to mutations in the 
COL4A3 and COL4A4 genes, located in 2q36–37, and is reported in 15% of families in European 
countries [8–10]. Autosomal recessive transmission due to COL4A3 and COL4A4 mutations is 
suggested by the presence of one of the following features: (i) severe early disease in both females 
and males; (ii) absence of severe signs in parents (they may be completely asymptomatic or may 
have isolated microhaematuria); (iii) parental consanguinity. 
The autosomal dominant form of ATS has been described more recently (ADAS, OMIM 104200). 
In 1997, this form had been linked to the COL4A3/COL4A4 locus in a large family from Northern 
Ireland and 3 years later there came the first report of a COL4A3 heterozygous mutation 
segregating in a family with ADAS [11,12]. Till now, only nine families with ADAS and a proven 
COL4A4 or COL4A3 mutation have been reported. Both female and male patients showed a high 
clinical variability with a renal phenotype ranging from isolated haematuria to late onset ESRD, 
associated in few instances with hearing loss [11–15]. 
Heterozygous mutations in COL4A4 or COL4A3 genes have been found also in the subset of 
patients with ‘Benign Familial Hematuria’ (BFH, OMIM 141200). BFH is clinically defined by 
persistent glomerular haematuria and by the absence of extra-renal findings [16–18]. The typical 
ultrastructural findings are diffuse thinning of GBM. 
Although the term ‘Thin Basement Membrane Nephropathy’ (TBMN) is a pure morphological 
definition, it is still erroneously used to describe patients with the diagnosis of BFH. In fact, the 
finding of isolated thinning of the basement membrane can represent the only lesion identified in 
patients with ATS [19]. 
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In this study, we present eight ATS families with autosomal dominant transmission and 
heterozygous mutations in the COL4A4 gene. The aim of this study is to better define the natural 
clinical history of ADAS in order to help in the differential diagnosis with the other known forms of 
ATS and with BFH. 
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RESULTS 
A COL4A4 mutation in eight families with ADAS has been identified by DHPLC analysis (Figure 
1). Detailed clinical information of a total of 38 patients belonging to these eight families has been 
collected (Table 1). The molecular diagnosis was confirmed in 29/38 patients. The remaining nine 
patients were either deceased or unavailable. 
COL4A4 mutations 
The eight identified pathogenic mutations were all in a heterozygous state, private and previously 
not described (Supplementary Figure 1). Seven mutations were distributed in the collagenic 
domain, and one mutation was localized in the C-terminal domain (Figure 2a). Three were 
frameshift mutations leading to a protein truncation within the collagenous domain (families MVA 
and MRM) or in the C-terminal domain in one family (family EVI). Three were missense mutations 
leading to glycine substitutions in the collagenous domain (families GEI, PUX and LCR). Two 
were splice-site mutations localized in intron 28 and 35 (families DAG and FRI). 
COL4A4 Mutations 
During the DHPLC screening, we also identified 11 previously reported polymorphisms and one 
rare variant (Table 2). 
Clinical data 
Clinical features of the 38 affected individuals are described in Table 1. Their mean age is 34 years 
(range from 6 to 76 years). Six patients died with ESRD at the mean age of 58.3 years (range, 46–
68 years). The main clinical manifestation was microscopic haematuria, which was present in 100% 
of patients. Gross haematuria occurred in 2/37 patients (5.4%). Proteinuria was present in 18/36 
patients with known urinalysis (50%). Renal failure occurred in 12/37 patients (32.4%). Among 
these, three patients aged 34, 43 and 49 years presented CRF (creatinine 1.48 mg/dl and 1.53 mg/dl 
in the last two cases). The remaining nine patients developed ESRD: six patients reached ESRD 
after the age of 40 years, at a mean age of 51.2 year (range, 42–67 years), two died at 60 and 66 
years of age and for the last patient no clinical data are available. 
An ultrastructural examination of the GBM was performed in 8 patients (range of age at renal 
biopsy from 14 to 43 years) belonging to seven families. Alterations of GBM were identified in all. 
In six patients, the ultrastructural alterations were clearly diagnostic for ATS, showing a 
combination of thinning, thickening and splitting of the GBM, while in two patients isolated GBM 
thinning was identified (EVI-II2, age at biopsy 26 years and DAG II1, age at biopsy 29 years). 
Bilateral hearing deficit in the 2000–8000 HZ range, with an onset after 40 years, developed in 4 of 
30 tested patients (13.3%). Ocular changes were found in 1 of 30 tested patients (3.3%): this 
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patient, aged 55 years, presented bilateral cataract post-renal transplantation attributed to steroid 
therapy. 
 
DISCUSSION 
ATS and BFH are type IV collagen inherited disorders associated with heterozygous mutations in 
COL4A3 and COL4A4 genes. Till now, only 43 patients belonging to nine families with ADAS 
have been reported with either COL4A3 or COL4A4 mutations [11–15]. 
In this study, we showed the clinical outcome and the molecular data of 38 patients with ADAS 
belonging to eight families in whom a pathogenic COL4A4 mutation was identified (Table 1). 
In this series of patients, haematuria, usually microscopic, was present in all cases with known urine 
analysis, while proteinuria was present in nearly 40% of patients. The development of renal failure 
was progressive with the age (Figure 3): only one patient (7.1%) younger than 40 years (1/14) 
presented CRF; two patients among those aged between 41 and 50 years (2/10; 20%) showed renal 
failure (one patient with ESRD and one patient with CRF); among patients aged between 51 and 60 
years, four developed ERSD (4/6; 67%) and four out of five patients older than 60 years developed 
ESRD (80%). 
GBM alterations were identified in all patients in whom a renal biopsy was performed. Only for one 
family, renal biopsy has not been performed. However, the hypothesis of a diagnosis of ATS is 
propped by the clinical manifestation of affected members of the family and by the identification of 
a disease segregating mutation in the COL4A4 gene leading to a glycine substitution in the 
collagenous domain of the protein [5]. The ultrastructural study of renal biopsy in almost all 
patients revealed a combination of thickening, splitting and thinning of the GBM. It is worth noting 
that two unrelated patients (aged 26 and 29 years) showed isolated thinning of GBM. This 
observation emphasizes the concept that thinning of the GBM is a non-specific finding and can be 
predictable of either BFH or ATS [15,19]. Recently, Voskarides K. et al. reported eight families 
with heterozygous COL4A3 mutations and a phenotype that in some patients was present in 
isolated haematuria while in older relatives progressed to CRF/ESRD [20]. The only ultrastructural 
finding in tested patients was a thinning of the GBM, and the authors defined these families as 
affected by TBMN [20]. Since TBMN is a term often associated with a benign prognosis, these 
patients could be rather classified as ADAS. 
The extra-renal manifestations typical of ATS have not been frequently observed in our cohort of 
patients. Only 13% of patients developed sensorineural hearing loss that was slowly progressive. 
The only patient with ocular abnormalities in our series was a 55-year-old male patient who 
developed bilateral cataract post-renal transplantation, probably due to steroid treatment. The 
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occurrence of congenital or early onset cataract has been already reported although in a minority of 
patients with a definitive diagnosis of ATS [5]. 
In all our patients, a heterozygous mutation in the COL4A4 gene has been identified. These 
mutations are of different type and are scattered throughout the gene. Heterozygous mutations in 
COL4A3 and COL4A4 are associated with a wide spectrum of phenotypes ranging from isolated 
microhaematuria to ESRD, as highlighted also by the intra- and inter-clinical variability reported in 
ADAS [16,17,21–23]. The intra-familial clinical variability observed in our cohort of patients was 
mainly due to the age at examination. However, some relatives showed a different clinical outcome 
at nearly the same age as in the case of family FRI where patient II3 developed ESRD at the age of 
45 years while patient III2 showed isolated microhaematuria at the age of 42 years. The intra-
familial clinical variability was more evident in families previously reported where even non-
penetrant cases have been observed [15]. An inter-familial clinical variability was also present in 
our cases; in fact, while in nearly all families, older patients developed renal failure, in family LCR 
a male patient aged 76, and showed normal blood creatinine. 
In order to explain such variability, we can hypothesize that the type and/or site of the mutation 
may be critical, even if genotype–phenotype correlations are made difficult by the fact that the 
mutations in these genes are often private and there are not mutational hot spots. However, 
analysing our cases and those already reported, it seems that there is not a clear correlation between 
type of mutation and phenotype. In fact, mutations of each type (missense, splice site and 
frameshift) and distributed throughout the genes are reported both in isolated microhaematuria 
segregating families and in families with progression towards ESRD (ADAS phenotype) (Figure 2a 
and b). The lack of a genotype–phenotype correlation is also highlighted by the different clinical 
outcome of patients of the same age, within a family, and thus bearing the same mutation. If the 
mutation alone cannot explain the clinical variability, we can suppose that the effect of a pathogenic 
mutation could be influenced by the presence of certain polymorphisms in the same genes and/or 
that functional variants in other proteins that are key players in renal filtration may act as modifiers. 
We have compared the frequency of each sign among our patients and ADAS cases already 
reported in the literature, considering together patients with COL4A3 or COL4A4 gene mutations, 
given the low number of families reported with mutations in each gene (Table 3) [5,6,12–15]. 
Haematuria, usually microscopic, is the cardinal feature of the disease and was present in all 
patients with known urinanalysis, both in our patients and in patients previously reported. 
Proteinuria was present in about half of cases. Furthermore, our observations confirmed previously 
reported data about the slow progression towards ESRD and the lower occurrence of extra-renal 
signs [12–15]. 
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Overall, the clinical outcome of ADAS seems to be close to XLAS in carrier females (Table 3). 
However, carriers of the XLAS have a higher incidence of proteinuria as presenting feature (75% 
versus 40–50%), while they have a lower progression towards ESRD than patients with ADAS, 
being reported in about 18% of females with XLAS [6]. Concerning the extra-renal manifestations, 
the development of hearing loss is comparable between the two groups (20–30%), while ocular 
lesions have never been reported in ADAS patients and are present in about 15% of XLAS carriers. 
ADAS is suggested by a similar clinical outcome in males and females and vertical transmission of 
clinical signs. Clinically it is characterized by the presence of microhaematuria, ESRD onset usually 
after 40 years, ultrastructural changes of the GBM from isolated thinning to a combination of 
thinning, thickening and splitting, and presence of slowly progressive hearing loss in about 20% of 
cases. Even if ocular signs have never been reported, a low prevalence in ADAS cannot be 
excluded. 
In conclusion, it is very difficult to predict the prognosis in a patient with a heterozygous mutation 
in either the COL4A3 or the COL4A4 gene. A correct diagnosis and prognosis is based on a 
combination of a comprehensive clinical investigation of all family members, including 
examination of renal and extra-renal signs of ATS in older members, associated with a broadly 
formal genetic analysis of the pedigree. 
 
METHODS 
 
Patients 
Thirty-eight patients belonging to eight families with a clinical suspect of ADAS were enrolled in 
this study. Patients were diagnosed by experienced nephrologists and clinical geneticists. Urinalysis 
and renal function evaluations were performed in all patients. Audiological and ophthalmic 
examinations were performed in several patients. Whenever indicated, a renal biopsy with 
ultrastructural study by electron microscopy was performed. 
 
Mutation analysis 
Blood samples were collected from patients after informed consent. Genomic DNA was extracted 
using a QIAamp DNA blood maxi kit, according to the manufacturers’ protocol (Quiagen, Hilden, 
Germany). All the COL4A4 exons were amplified using the primers and PCR condition already 
described [14]. Mutation analysis was performed by denaturing high performance liquid 
chromatography (DHPLC) using Transgenomic WAVETM (Transgenomic, San Jose, CA, USA) 
and by subsequent genomic sequencing analysis. PCR products were denatured at 95°C, re-
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annealed at 65°C for 10 min and cooled at 4°C to generate heteroduplex [15]. The optimal column 
temperature for fragments analysis was calculated using the WaveMaker Software (Transgenomic, 
San Jose, CA, USA). DHPLC analysis was performed at the melting temperature of 60°C for exon 
25, 60.2°C for exon 22, 60.6°C for exon 28, 57.7°C for exon 46, 55.3°C for exon 35 and 54°C for 
exon 16. PCR products resulting in abnormal DHPLC profiles were purified and sequenced on both 
strands by using a PE Big dye terminator cycle sequencing kit on an ABI Prism 310 genetic 
analyser (PE Applied Biosystems, Foster City, CA, USA). Segregation analysis was performed by 
direct sequencing in all families. 
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Fig. 1 
Pedigree of families. The figure represents the pedigree of family 1 (a), 2 (b), 3 (c), 4 (d), 5 (e), 6 
(f), 7 (g), 8 (h).   Males, females. Filled grey symbols are individuals with isolated 
microhaematuria. Filled black symbols indicate individuals with microhaematuria plus 
macrohaematuria or proteinuria or hypoacusia or renal failure. White symbols indicate individuals 
without clinical sings of the disease. An oblique bar indicates a deceased individual. The arrows 
indicate the index patients. The genotype at the COL4A4 locus is indicated below each symbol as 
follows: −, wild type allele; +, mutated allele. The type of mutation is indicated in brackets: f = 
frameshift mutation; m = missense mutation; s = splice site mutation. In (a) case I-2 has 
microhaematuria probably not related to ATS. 
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Fig. 2 
Distribution of pathogenetic mutations along COL4A4 (A) and COL4A3 (B) genes in ADAS 
patients. *mutations previously reported as associated with ADAS. All the others are novel 
mutations reported here. 
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Fig. 3 
Graphic representing the phenotype of our 35 patients at different ages. Patients have been divided 
in four classes of age (0–20; 21–40; 41–60; 61–80) and they have been classified according to their 
renal involvement. The white bar represents patients with isolated microhaematuria, the grey bar 
represents cases with microhaematuria and proteinuria and the black bar represents patients with 
renal failure (both IRC and ESRD). Above each column, the absolute number of patients is 
reported. 
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Table 1 
Clinical and molecular data of reported patients 
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Family/su
bject 
Sex Age Urinalysis Renal 
function 
GBM 
abnor
malitie
s 
Ophthalmic 
examination 
Audiological 
examination 
COL4A4 heterozygous mutation COL4A4 
heterozy
gous 
polymor
phisms 
        Nucleotide 
change 
Effect on 
coding 
Exon/intron  
         sequence   
MVA/I1 M 55 Microhaematu
ria 
Normal n.d. Normal Mild h.l. 1884–1886del C P629fsX652 Exon 25 1, 4, 5, 
11 
MVA/II1 F 25 Microhaematu
ria 
 proteinuria 
Normal Thinnin
g, 
 thicke
ning 
Normal Normal 1884–1886del C P629fsX652 Exon 25 1, 4, 6, 7, 
8, 9, 10, 
12 
            
MRM/II3 M 43 Microhaematu
ria 
 proteinuria 
CRF at 40 
year 
Thicke
ning 
Normal Normal 1579–1581del G G527fsX652 Exon 22 None 
MRM/III1 F 15 Microhaematu
ria 
 proteinuria 
Normal n.d. Normal Normal 1579–1581del G G527fsX652 Exon 22 None 
MRM/I1 F 50 Microhaematu
ria 
ESRD at 
46 year 
n.d. Normal Normal n.a. n.a. n.a. n.a. 
MRM/I2 M 68 Microhaematu
ria 
ESRD at 
67 year 
n.d. Normal s.h.l. n.a. n.a. n.a. n.a. 
MRM/II1 M 44 Microhaematu
ria 
Normal n.d. Normal n.d. n.a. n.a. n.a. n.a. 
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 proteinuria 
MRM/II4 F 40 Microhaematu
ria 
 proteinuria 
Normal n.d. Normal n.d. n.a. n.a. n.a. n.a. 
            
EVI/II2 M 33 Microhaematu
ria 
 proteinuria 
Normal Thinnin
g 
Normal c.h.l. 4493–4495 del G G1498fsX155
1 
Exon 46 5, 6, 7, 8, 
9, 10, 11, 
12 
EVI/I2 M 46 Microhaematu
ria 
 proteinuria 
ESRD at 
42 year 
n.d. Normal Normal n.a. n.a. n.a. n.a. 
EVI/I3 M 60 Microhaematu
ria 
 proteinuria 
n.d. n.d. Normal Normal n.a. n.a. n.a. n.a. 
            
GEI/III2 F 7 Microhaematu
ria 
Normal n.d. Normal Normal 1837G>A G613R Exon 25 3, 4, 6, 7, 
11, 12 
GEI/II2 M 45 Microhaematu
ria 
Normal n.d. Normal Mild h.l. 1837G>A G613R Exon 25 2, 5, 6, 7, 
8, 9, 10, 
11, 12 
GEI/I1 F 60^ n.d. ESRD n.d. n.d. n.d. n.a. n.a. n.a. n.a. 
GEI/II4 F 41 Microhaematu
ria 
Normal n.d. n.d. n.d. 1837G>A G613R Exon 25 2, 5, 6, 7, 
8, 9, 10, 
11, 12 
            
PUX/I1 F n.d. n.d. ESRD n.d. n.d. n.d. 940G>T G314C Exon 16 None 
PUX/II1 M 48 Microhaematu Normal Thinnin n.d. n.d. 940G>T G314C Exon 16 6, 7, 8, 9, 
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ria 
 proteinuria 
g, 
 splitti
ng 
10, 11, 
12 
PUX/III1 F 7 Microhaematu
ria 
Normal n.d. Normal Normal 940G>T G314C Exon 16 None 
            
LCR/I2 M 76 Microhaematu
ria 
Normal n.d. Normal s.h.l. 1579G>T G527C Exon 22 2, 5, 6, 7, 
8, 9, 10, 
11, 12 
LCR/II1 F 47 Microhaematu
ria 
Normal n.d. Normal Normal 1579G>T G527C Exon 22 None 
LCR/II3 M 40 Microhaematu
ria 
Normal n.d. Normal Normal 1579G>T G527C Exon 22 2, 5, 6, 7, 
8, 9, 10, 
11, 12 
LCR/III1 F 26 Micro-
macrohaematu
ria proteinuria 
Normal Thinnin
g, 
 thicke
ning, 
 splitti
ng 
Normal Normal 1579G>T G527C Exon 22 8, 9, 
LCR/III2 F 21 Micro-
macrohaematu
ria 
Normal Thinnin
g, 
 thicke
ning, 
 splitti
ng 
Normal Normal 1579G>T G527C Exon 22 None 
LCR/III3 M 11 Microhaematu Normal n.d. Normal Normal 1579G>T G527C Exon 22 2, 6, 7, 8, 
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ria 9, 10, 11, 
12 
            
DAG/I1 M 73 Microhaematu
ria 
 proteinuria 
ESRD at 
60 year 
n.d. Normal Normal IVS28+2 T>G IVS28+2 T>G Intron 28 4, 6, 7, 8, 
9, 10, 11, 
12 
DAG/II1 M 49 Microhaematu
ria 
 proteinuria 
CRF Thinnin
g 
n.d. Normal IVS28+2 T>G IVS28+2 T>G Intron 28 2, 4, 5, 
DAG/III1 M 20 Microhaematu
ria 
Normal n.d. n.d. n.d. IVS28+2 T>G IVS28+2 T>G Intron 28 4, 6, 7, 8, 
9, 10, 11, 
12 
DAG/III2 F 11 Microhaematu
ria 
Normal n.d. n.d. n.d. IVS28+2 T>G IVS28+2 T>G Intron 28 5 
            
FRI/I2 F 66 Microhaematu
ria 
 proteinuria 
ESRD n.d. Normal Normal n.a. n.a. n.a. n.a. 
FRI/II2 F 64 Microhaematu
ria 
 proteinuria 
ESRD at 
60 year 
n.d. Normal Normal IVS35+1G>A IVS35+1G>A Intron 35 None 
FRI/II3 M 55 Microhaematu
ria 
 proteinuria 
ESRD at 
45 year 
Thinnin
g, 
 thicke
ning, 
 splitti
ng 
Cataract 
post-tx 
Normal IVS35+1G>A IVS35+1G>A Intron 35 2, 5, 6, 7, 
8, 9, 10, 
11, 12 
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FRI/III2 M 42 Microhaematu
ria 
Normal n.d. Normal Normal IVS35+1G>A IVS35+1G>A Intron 35 2, 5, 6, 7, 
8, 9, 10, 
11, 12 
FRI/III3 F 40 Microhaematu
ria 
 proteinuria 
Normal n.d. Normal Normal IVS35+1G>A IVS35+1G>A Intron 35 2, 5, 6, 7, 
8, 9, 10, 
11, 12 
FRI/III6 M 34 Microhaematu
ria 
 proteinuria 
CRF n.d. Normal Normal IVS35+1G>A IVS35+1G>A Intron 35 None 
FRI/IV1 F 16 Microhaematu
ria 
 proteinuria 
Normal n.d. n.d. Normal IVS35+1G>A IVS35+1G>A Intron 35 2, 5, 6, 7, 
10, 11, 
12 
FRI/IV3 F 11 Microhaematu
ria 
Normal n.d. Normal Normal IVS35+1G>A IVS35+1G>A Intron 35 2, 5, 6, 7, 
10, 11, 
12 
FRI/IV4 M 9 Microhaematu
ria 
Normal n.d. Normal Normal IVS35+1G>A IVS35+1G>A Intron 35 2, 5, 6, 7, 
10, 11, 
12 
FRI/IV5 F 6 Microhaematu
ria 
Normal n.d. Normal Normal IVS35+1G>A IVS35+1G>A Intron 35 2, 6, 7, 
10, 11, 
12 
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Table 2 
Polymorphisms in the COL4A4 gene 
 
Nucleotide 
change 
Effect on coding sequence Exon/intron  
1 IVS5+86C>Ta IVS5+86C>Ta Intron 5 
2 1444C>T P482S Exon 21 
3 1634G>C G545A Exon 23 
4 IVS28–5C>T IVS28–5C>T Intron 28 
5 3011T>C L1004P Exon 33 
6 3594G>A G1198G Exon 39 
7 3684G>A K1228K Exon 39 
8 4080A>G P1360P Exon 42 
9 3979A>G M1327V Exon 42 
10 4204C>T P1402S Exon 44 
11 4548A>G V1516V Exon 47 
12 4932C>T F1644F Exon 48 
  aNot reported as polymorphism (rare variant). 
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Table 3 
Clinical features of the 38 patients, in comparison with previously reported ADAS [12–15] and 
XLAS [5,6] patients 
 
 Present 
study 
ADAS 
literature 
ADAS total XLAS 
males 
XLAS females 
Number of patients 38 43 79 218 349 
Microhaematuria 100% (38/38) 94.3% (33/35) 97.3% (71/73) 100% 95.5% 
Proteinuria 50% (18/36) 41.2% (14/34) 45.7% (32/70) 95% 75.20% 
Hearing loss 13.3% (4/30) 27% (10/37) 20.9% (14/67) 79% 28% 
Ocular lesions 0/29 0 0 35.2% 15% 
ERSD      
 Onset: <31 year 0% (0/6) 0% (0/8) 0% (0/14) 76.5% 24% 
 Onset: 31–40 
years 
0% (0/6) 12.5% (1/8) 7.1% (1/14) 17.5% 31% 
 Onset:>40 year 100% (6/6) 87.5% (7/8) 92.8% (13/14) 6% 41% 
 
